You searched for "IOL"
RCOphth 2024 Report
A comprehensive tapestry of all our RCOphth Annual Congress content captured between 20–23 May 2024.‘Agenda-setting’ BCLA Clinical Conference to shape the future of contact lens practice around the world
The global eye care professional network’s “unquenchable thirst for learning” ensured the success of the first in-person BCLA Clinical Conference & Exhibition in four years.The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD
Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...Personalising the management of dry eye disease: TFOS DEWS III updates evidence-based recommendations
Dry eye disease (DED) is a heterogenous condition that arises from various aetiologic factors and leads to tear film instability, ocular surface damage and neurosensory changes. Symptoms of DED include ocular dryness, burning, itching, pain and visual impairment. An evidence-based...The implementation of postoperative day 1 vitrectomy telephone follow-up consultations
In this pre-COVID-19 study, the authors argue that some follow-up consultations can be done by telephone without compromising patient safety. Thirty years ago, a study by Isernhagen et al. [1] found that 52% of patients required some form of unexpected...Improving cataract efficiency: insights and learnings from expert practitioners
An evening surgical meeting sponsored by Théa Pharmaceuticals Ltd brought together leading experts to share insights and experience on practice strategies to enhance the efficiency of cataract surgery. Streamlining patient flow to optimise capacity and efficiency Qasim Mansoor, Consultant Ophthalmic...
Aflibercept for the treatment of neovascular glaucoma
The aim of this study was to investigate initial results regarding the treatment of neovascular glaucoma (NVG) with intravitreal aflibercept. NVG is classified into stages 0-3. In stages 1 and 2, abnormal vessel proliferation is seen with or without elevated...
Sustained elevation of extracellular ATP in chronic glaucoma
Although adenosine 5′-triphosphate (ATP) release from retinal neurons and astrocytes has been demonstrated in short-term increases in intraocular pressure (IOP); such as in aqueous humor of humans with primary acute angle closure glaucoma, the response in chronic IOP elevation was...
Canaloplasty after failed trabeculectomy
The authors describe the technique of canaloplasty performed in five patients who had undergone previous trabeculectomy and under maximum tolerated medical therapy or insufficient intraocular pressure (IOP) control. Canaloplasty is described by the authors as “a nonperforating blebless technique derived...
Nanoparticle administration of latanoprost
Glaucoma is a progressive optic neuropathy characterised by increased ocular pressure and loss of retinal ganglion cells. Conventional drug therapy with eye drops to reduce intraocular pressure (IOP) has variable bioavailability and can lead to ocular surface disease. In this...
SLT versus medication for OAG
This paper appraised existing randomised clinical trials (RCTs), which compared selective laser tabeculoplasty (SLT) with medical therapy for open-angle glaucoma (OAG), and performed a systematic review and meta-analysis. A total of 1229 patients in eight trials were included from PubMed,...
